New drug combo aims to keep childhood leukemia at bay after transplant
NCT ID NCT07012044
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have already received a stem cell transplant. The goal is to see if this maintenance therapy can help prevent the leukemia from coming back without causing severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX727 (cedazuridine and decitabine) and filgrastim
What this could lead to
If it works, this could provide a safer maintenance option after stem cell transplant to help prevent leukemia relapse in children.
What could go wrong
This is an early phase 1 trial with only 47 participants, so safety and dosing are still being determined. It may not work or could cause serious side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Alabama
RECRUITINGBirmingham, Alabama, 35233, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact Phone: •••-•••-••••
-
Riley Hospital for Children
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Phone: •••-•••-••••
-
Saint Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota/Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact
Contact Phone: •••-•••-••••